SV2005002129A - Nuevos derivados de aminopiridina y su uso como farmacos ref. pc32360a - Google Patents
Nuevos derivados de aminopiridina y su uso como farmacos ref. pc32360aInfo
- Publication number
- SV2005002129A SV2005002129A SV2005002129A SV2005002129A SV2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A SV 2005002129 A SV2005002129 A SV 2005002129A
- Authority
- SV
- El Salvador
- Prior art keywords
- sexual
- disorder
- disorders
- compounds
- dysfunction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA COMPUESTOS DE FORMULA (I): (VER FORMULA) QUE SON UNA CLASE DE AGONISTAS DE DOPAMINA, MAS PARTICULARMENTE UNA CLASE DE AGONISTAS QUE SON SELECTIVOS PARA D3 SOBRE D2. ESTOS COMPUESTOS SON UTILES PARA EL TRATAMIENTO Y/O PREVENCION DE LA DISFUNCION SEXUAL, POR EJEMPLO LA DISFUNCION SEXUAL FEMENINA (FSD), EN PARTICULAR EL TRASTORNO DE LA EXCITACION SEXUAL FEMENINA (FSAD), TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERES EN EL SEXO), TRASTORNO ORGASMICO FEMENINO (FOD; INCAPACIADAD PARA ALCANZAR EL ORGASMO); Y LA DISFUNCION SEXUAL MASCULINA, EN PARTICULAR LA DISFUNCION ERECTIL MASCULINA (MED). LA DISFUNCION SEXUAL MASCULINA SEGUN SE REFIERE EN LA PRESENTE MEMORIA SE SUPONE QUE INCLUYE TRASTORNOS EYACULATORIO TALES COMO EYACULACION PRECOZ, ANORGASMIA (INCAPACIDAD PARA ALCANZAR EL ORGASMO) O TRASTORNOS DEL DESEO TALES COMO EL TRASTORNO DEL DESEO SEXUAL HIPOACTIVO (HSDD; FALTA DE INTERES EN EL SEXO). ESTOS COMPUESTOS TAMBIEN SON UTILES PARA TRATAR TRASTORNOS NEUROPSIQUIATRICOS Y TRASTORNOS NEURODEGENERATIVOS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2005002129A true SV2005002129A (es) | 2005-12-13 |
Family
ID=34970000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2005002129A SV2005002129A (es) | 2004-05-27 | 2005-05-27 | Nuevos derivados de aminopiridina y su uso como farmacos ref. pc32360a |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1758862A1 (es) |
JP (1) | JP4198183B2 (es) |
AP (1) | AP2006003824A0 (es) |
AR (1) | AR049548A1 (es) |
AU (1) | AU2005247699A1 (es) |
BR (1) | BRPI0511571A (es) |
CA (1) | CA2567935C (es) |
EA (1) | EA200601982A1 (es) |
EC (1) | ECSP067029A (es) |
GT (1) | GT200500125A (es) |
IL (1) | IL179314A0 (es) |
MA (1) | MA28607B1 (es) |
MX (1) | MXPA06013786A (es) |
NL (1) | NL1029139C2 (es) |
NO (1) | NO20065326L (es) |
PA (1) | PA8635101A1 (es) |
PE (1) | PE20060366A1 (es) |
SV (1) | SV2005002129A (es) |
TW (1) | TW200609216A (es) |
UY (1) | UY28925A1 (es) |
WO (1) | WO2005115985A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0502509D0 (en) | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
JP5777526B2 (ja) * | 2009-02-13 | 2015-09-09 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 縮合ピリミジン類 |
ES2552166T3 (es) * | 2010-04-12 | 2015-11-26 | Supernus Pharmaceuticals, Inc. | Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas |
JP6075654B2 (ja) | 2011-06-30 | 2017-02-08 | ドナルドソン カンパニー,インコーポレイティド | 空気/油分離装置アセンブリ、部品及び方法 |
GB2543296A (en) * | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
CN109641871B (zh) | 2016-07-20 | 2021-10-22 | 诺华股份有限公司 | 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途 |
AU2020270992A1 (en) * | 2019-04-12 | 2021-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
IL293085A (en) | 2019-11-22 | 2022-07-01 | Incyte Corp | Combined treatment that includes an alk2 inhibitor and a jak2 inhibitor |
TW202214239A (zh) | 2020-06-16 | 2022-04-16 | 美商英塞特公司 | 用於治療貧血之alk2抑制劑 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
RS51442B (en) * | 2002-12-10 | 2011-04-30 | Pfizer Inc. | MORPHOLINE DERIVATIVES USED AS DOPAMINE AGONISTS IN TREATMENT I.A. SEXUAL DYSFUNCTIONS |
-
2005
- 2005-05-17 CA CA002567935A patent/CA2567935C/en not_active Expired - Fee Related
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/en active Application Filing
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/xx unknown
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/pt not_active Application Discontinuation
- 2005-05-17 EP EP05747191A patent/EP1758862A1/en not_active Withdrawn
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/ja not_active Expired - Fee Related
- 2005-05-17 EA EA200601982A patent/EA200601982A1/ru unknown
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/es not_active Application Discontinuation
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-24 GT GT200500125A patent/GT200500125A/es unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/es not_active Application Discontinuation
- 2005-05-26 UY UY28925A patent/UY28925A1/es not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/zh unknown
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/es unknown
- 2005-05-26 NL NL1029139A patent/NL1029139C2/nl not_active IP Right Cessation
- 2005-05-26 AR ARP050102169A patent/AR049548A1/es unknown
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/es not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/no unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/fr unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2008500331A (ja) | 2008-01-10 |
AR049548A1 (es) | 2006-08-16 |
AP2006003824A0 (en) | 2006-12-31 |
UY28925A1 (es) | 2005-12-30 |
ECSP067029A (es) | 2006-12-29 |
NO20065326L (no) | 2006-12-19 |
IL179314A0 (en) | 2007-03-08 |
EA200601982A1 (ru) | 2007-04-27 |
PE20060366A1 (es) | 2006-05-15 |
CA2567935A1 (en) | 2005-12-08 |
AU2005247699A1 (en) | 2005-12-08 |
TW200609216A (en) | 2006-03-16 |
NL1029139A1 (nl) | 2005-11-30 |
JP4198183B2 (ja) | 2008-12-17 |
PA8635101A1 (es) | 2006-05-16 |
NL1029139C2 (nl) | 2006-06-19 |
EP1758862A1 (en) | 2007-03-07 |
WO2005115985A1 (en) | 2005-12-08 |
BRPI0511571A (pt) | 2008-01-02 |
GT200500125A (es) | 2006-01-10 |
MXPA06013786A (es) | 2007-01-25 |
CA2567935C (en) | 2009-10-27 |
MA28607B1 (fr) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2005002129A (es) | Nuevos derivados de aminopiridina y su uso como farmacos ref. pc32360a | |
CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
CL2017003404A1 (es) | Compuestos antibacterianos | |
CL2017002150A1 (es) | Receptores de antígeno quiméricos anti-dll3 y métodos de uso | |
SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
DOP2015000274A (es) | Compuestos químicos | |
CL2016000341A1 (es) | Métodos para tratar la miositis por cuerpos de inclusión esporádica | |
MY195437A (en) | Methods of Treatment for Cholestatic and Fibrotic Diseases | |
CL2015002675A1 (es) | Composiciones de arnm de cftr y métodos y usos relacionados | |
UY35682A (es) | Anticuerpos anti-activina a y usos de los mismos | |
CO6430487A2 (es) | Anticuerpos anti-her | |
PE20190973A1 (es) | Compuestos de tetrahidropirazolopirimidina | |
CL2016000556A1 (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso. | |
SV2017005368A (es) | [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
CR20150496A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
AR072425A1 (es) | Uso de nifurtimox para el tratamiento de giardiasis | |
CU20150176A7 (es) | Derivados de prodroga de triazolpiridinas sustituídas | |
CY1120178T1 (el) | Αγωγη εμμηνοπαυσιακων εξαψεων με ροπινιρολη και τιζανιδινη | |
SV2005002128A (es) | "nuevos derivados de indazol e indolona y su uso como productos farmaceuticos" ref. pc32256a | |
CL2015003460A1 (es) | Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica | |
BR112016000431A8 (pt) | composições e métodos para o tratamento de distúrbios neuropsiquiátricos usando um agonista do receptor de endotelina-b | |
AR100444A1 (es) | Uso de palmitoiletanolamida en combinación de opioides | |
CL2015001438A1 (es) | Derivados de pregnenolona. | |
DOP2005000095A (es) | Nuevos derivados de aminopiridina y su uso como farmacos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Lapse |